Payment overview · 2025
General Payments
$2,532.32
128 reported records · 32 companies
Healthcare provider profile · identity verified
Mandeep Garewal, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Diagnostic Neuroimaging · ORMOND BEACH, FL · NPI 1700997707
Verified facts
What the public records show
CMS Open Payments records show Mandeep Garewal, MD received $2,532.32 in general payments during 2025 across 128 reported records.
ABBVIE INC. accounted for 12.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Panzyga, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Qulipta by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gamunex-C by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Apokyn as an associated drug or biological on 1207 records involving 338 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Apokyn by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Panzyga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Panzyga by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.72 | 12.1% | 15 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $237.41 | 9.4% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $213.07 | 8.4% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $158.86 | 6.3% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.03 | 5.7% | 9 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $142.06 | 5.6% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $137.31 | 5.4% | 7 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $119.24 | 4.7% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $114.88 | 4.5% | 9 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $113.74 | 4.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $92.81 | 3.7% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $74.58 | 3.0% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $73.96 | 2.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.28 | 2.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.49 | 2.7% | 3 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.19 | 2.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $58.71 | 2.3% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.82 | 1.6% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $38.78 | 1.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.24 | 1.0% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $24.23 | 1.0% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.79 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.28 | 0.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $22.00 | 0.9% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $20.82 | 0.8% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$19.55 | 0.8% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $19.05 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 0.7% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $17.21 | 0.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $16.19 | 0.6% | 1 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $16.12 | 0.6% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $14.00 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,414.83 | 125 |
| Education | $109.15 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8.34 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $235.07 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $191.72 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $146.16 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $142.06 | 8 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $137.31 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $132.99 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $124.04 | 10 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $119.24 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $113.74 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $106.50 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $106.50 | 7 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $89.28 | 6 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $74.58 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $73.96 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $72.28 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.49 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $68.03 | 3 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $65.19 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.05 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.05 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| MAYZENT Normalized: mayzent |
Drug | Novartis Pharmaceuticals Corporation | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $23.19 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $9.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Apokyn open payments reported associated product |
CMS Open Payments — General Payments 1207 supporting records · 338 recipient NPIs · example record 1241843684 |
Apokyn · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 914 | 264 |
| Gabapentin | Gabapentin | 506 | 148 |
| Donepezil Hcl | Donepezil Hcl | 498 | 170 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 429 | 140 |
| Clonazepam | Clonazepam | 367 | 71 |
| Alprazolam | Alprazolam | 320 | 84 |
| Levetiracetam | Levetiracetam | 280 | 81 |
| Tramadol Hcl | Tramadol Hcl | 267 | 50 |
| Propranolol Hcl | Propranolol Hcl | 251 | 81 |
| Pregabalin | Pregabalin | 238 | 68 |
| Temazepam | Temazepam | 179 | 35 |
| Lamotrigine | Lamotrigine | 172 | 43 |
| Rivastigmine | Rivastigmine Tartrate | 168 | 54 |
| Trazodone Hcl | Trazodone Hcl | 167 | 55 |
| Primidone | Primidone | 162 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 46 |
| Topiramate | Topiramate | 156 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 154 | 47 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 143 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 134 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 28 |
| Prednisone | Prednisone | 131 | 46 |
| Lorazepam | Lorazepam | 129 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 27 |
| Propranolol Hcl Er | Propranolol Hcl | 104 | 29 |
| Modafinil | Modafinil | 102 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 31 |
| Lidocaine | Lidocaine | 86 | 25 |
| Memantine Hcl Er | Memantine Hcl | 75 | 17 |
| Carbamazepine | Carbamazepine | 70 | 23 |
| Rivastigmine | Rivastigmine | 60 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | 20 |
| Diazepam | Diazepam | 53 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | suppressed |
| Aripiprazole | Aripiprazole | 50 | 18 |
| Baclofen | Baclofen | 50 | 23 |
| Eliquis | Apixaban | 50 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 50 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 48 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 41 | suppressed |
| Austedo | Deutetrabenazine | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 39 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | 11 |
| Ropinirole Er | Ropinirole Hcl | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | 11 |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | suppressed |
| Zonisamide | Zonisamide | 32 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 31 | suppressed |
| Lacosamide | Lacosamide | 30 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Neupro | Rotigotine | 27 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 23 | suppressed |
| Qulipta | Atogepant | 23 | suppressed |
| Teriflunomide | Teriflunomide | 23 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 21 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 20 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Dalfampridine Er | Dalfampridine | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Levetiracetam Er | Levetiracetam | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Carbidopa | Carbidopa | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Apokyn | Apomorphine Hcl | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Xcopri | Cenobamate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,532.32 · 128 records | ABBVIE INC. | AMVUTTRA, AMYVID, AUSTEDO XR, BOTOX, CREXONT, FIRDAPSE, FISHER & PAYKEL HEALTHCARE, GIVLAARI, Gamunex-C, Gocovri, HYQVIA, Hizentra, INGREZZA, INSPIRE, INTELLIS ADAPTIVESTIM, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, MAYZENT, NURTEC ODT, ONGENTYS, PANZYGA, PRECIVITYAD2, QULIPTA, Qelbree, REXULTI, Radicava, Rystiggo, UBRELVY, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND, ZEPOSIA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error